Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $2.1 million.

  • Enanta Pharmaceuticals' Other Accumulated Expenses fell 3189.66% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 million, marking a year-over-year decrease of 3189.66%. This contributed to the annual value of $1.8 million for FY2025, which is 4169.1% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Other Accumulated Expenses is $2.1 million, which was down 3189.66% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Other Accumulated Expenses ranged from a high of $14.4 million in Q1 2022 and a low of $1.5 million during Q1 2024
  • Over the past 5 years, Enanta Pharmaceuticals' median Other Accumulated Expenses value was $4.8 million (recorded in 2022), while the average stood at $4.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 14413.19% in 2021, then crashed by 7157.99% in 2024.
  • Enanta Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $6.4 million in 2021, then rose by 6.44% to $6.9 million in 2022, then tumbled by 45.98% to $3.7 million in 2023, then decreased by 18.64% to $3.0 million in 2024, then crashed by 31.9% to $2.1 million in 2025.
  • Its Other Accumulated Expenses was $2.1 million in Q4 2025, compared to $1.8 million in Q3 2025 and $2.4 million in Q2 2025.